A detailed history of Smith, Salley & Associates transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Smith, Salley & Associates holds 9,565 shares of BMY stock, worth $563,091. This represents 0.03% of its overall portfolio holdings.

Number of Shares
9,565
Previous 10,143 5.7%
Holding current value
$563,091
Previous $421,000 17.34%
% of portfolio
0.03%
Previous 0.03%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$39.66 - $51.75 $22,923 - $29,911
-578 Reduced 5.7%
9,565 $494,000
Q2 2024

Jul 29, 2024

SELL
$40.25 - $52.99 $209,461 - $275,759
-5,204 Reduced 33.91%
10,143 $421,000
Q1 2024

May 02, 2024

BUY
$47.98 - $54.4 $368,294 - $417,574
7,676 Added 100.07%
15,347 $832,000
Q4 2023

Jan 24, 2024

SELL
$48.48 - $57.85 $280,941 - $335,240
-5,795 Reduced 43.03%
7,671 $393,000
Q3 2023

Oct 27, 2023

BUY
$57.89 - $64.73 $53,085 - $59,357
917 Added 7.31%
13,466 $781,000
Q2 2023

Aug 04, 2023

SELL
$63.71 - $70.74 $9,556 - $10,611
-150 Reduced 1.18%
12,549 $802,000
Q1 2023

May 03, 2023

BUY
$65.71 - $74.53 $41,134 - $46,655
626 Added 5.19%
12,699 $880,000
Q4 2022

Feb 03, 2023

BUY
$68.48 - $81.09 $45,881 - $54,330
670 Added 5.88%
12,073 $868,000
Q3 2022

Nov 01, 2022

BUY
$0.13 - $76.84 $15 - $9,067
118 Added 1.05%
11,403 $811,000
Q2 2022

Aug 01, 2022

BUY
$72.62 - $79.98 $124,180 - $136,765
1,710 Added 17.86%
11,285 $868,000
Q1 2022

May 10, 2022

SELL
$61.48 - $73.72 $85,088 - $102,028
-1,384 Reduced 12.63%
9,575 $699,000
Q4 2021

Feb 10, 2022

SELL
$53.63 - $62.52 $136,756 - $159,426
-2,550 Reduced 18.88%
10,959 $683,000
Q3 2021

Nov 05, 2021

BUY
$59.17 - $69.31 $102,068 - $119,559
1,725 Added 14.64%
13,509 $799,000
Q2 2021

Aug 09, 2021

BUY
$61.91 - $67.42 $54,728 - $59,599
884 Added 8.11%
11,784 $788,000
Q1 2021

Apr 30, 2021

BUY
$59.34 - $66.74 $111,321 - $125,204
1,876 Added 20.79%
10,900 $688,000
Q4 2020

Jan 28, 2021

BUY
$57.74 - $65.43 $2,482 - $2,813
43 Added 0.48%
9,024 $559,000
Q3 2020

Nov 05, 2020

BUY
$57.43 - $63.64 $344 - $381
6 Added 0.07%
8,981 $541,000
Q2 2020

Aug 04, 2020

SELL
$54.82 - $64.09 $311,103 - $363,710
-5,675 Reduced 38.74%
8,975 $528,000
Q1 2020

Apr 24, 2020

SELL
$46.4 - $67.43 $155,068 - $225,351
-3,342 Reduced 18.57%
14,650 $817,000
Q4 2019

Jan 27, 2020

BUY
$49.21 - $64.19 $688,005 - $897,440
13,981 Added 348.57%
17,992 $1.16 Million
Q3 2019

Oct 30, 2019

BUY
$42.77 - $50.71 $171,550 - $203,397
4,011 New
4,011 $203,000
Q2 2019

Jul 12, 2019

SELL
$44.62 - $49.34 $263,213 - $291,056
-5,899 Closed
0 $0
Q1 2019

May 03, 2019

SELL
$45.12 - $53.8 $812 - $968
-18 Reduced 0.3%
5,899 $281,000
Q4 2018

Feb 05, 2019

SELL
$48.76 - $63.23 $2,779 - $3,604
-57 Reduced 0.95%
5,917 $308,000
Q3 2018

Nov 06, 2018

BUY
$55.19 - $62.25 $39,405 - $44,446
714 Added 13.57%
5,974 $371,000
Q2 2018

Aug 10, 2018

SELL
$50.53 - $62.98 $161,544 - $201,347
-3,197 Reduced 37.8%
5,260 $291,000
Q1 2018

May 09, 2018

BUY
$59.92 - $68.98 $10,006 - $11,519
167 Added 2.01%
8,457 $535,000
Q4 2017

Feb 12, 2018

BUY
$59.94 - $65.35 $7,972 - $8,691
133 Added 1.63%
8,290 $508,000
Q3 2017

Nov 02, 2017

BUY
$55.23 - $63.74 $450,511 - $519,927
8,157
8,157 $520,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Smith, Salley & Associates Portfolio

Follow Smith, Salley & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith, Salley & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Smith, Salley & Associates with notifications on news.